Diabetes, Obesity & Metabolism最新文献

{"title":"Vegetable-First Meal Sequence Suppresses Postprandial Glycaemic Excursions and Variability in Young Women With High-Risk Phenotype for Early-Onset Type 2 Diabetes: A 4-Arm Randomized Crossover Trial With Continuous Glucose Monitoring.","authors":"Minji Choi, Soyoon Lee, Eujean Bang, Ijae Seo, Jieun Lee, Sehyun Joo, Hyeonseo Kim, Song Vogue Ahn, Yuri Kim, Jieun Oh","doi":"10.1111/dom.71227","DOIUrl":"10.1111/dom.71227","url":null,"abstract":"<p><strong>Aims: </strong>Managing postprandial glycaemic variability is crucial for preventing metabolic diseases. Although the effects of a vegetable-first meal sequence on blood glucose levels have been well documented, there is limited research on consecutive, repeated meal sequencing for healthy young women. This study investigated the effects of 3-day repeated interventions on glycaemic profiles in this population.</p><p><strong>Materials and methods: </strong>In this randomized crossover trial, 33 healthy Korean women consumed isocaloric test meals under four conditions: (1) VPC (vegetables-protein-carbohydrates meal sequence) with 35 min meal limit; (2) CPV (carbohydrates-protein-vegetables meal sequence) with 35 min meal limit; (3) TGR (all together without sequence) with 35 min meal limit; (4) NTL (no meal intake time limit). Glycaemic profiles and variability were examined by continuous glucose monitoring over 3 h after each meal.</p><p><strong>Results: </strong>Compared to CPV, TGR and NTL, the VPC reduced the glucose incremental area under the curve for 0-1 h and 0-2 h and mean glucose for 0-1 h (p < 0.05). VPC also resulted in lower peak glucose and delayed time-to-peak compared to CPV (p < 0.0001). Time in range was the highest for VPC and VPC significantly reduced the mean amplitude of glycaemic excursion (MAGE) compared to all other sequences (p < 0.05).</p><p><strong>Conclusions: </strong>VPC improves postprandial glycaemic control, demonstrating consistent benefits across different meal constraints, including unrestricted eating (NTL). Optimizing meal sequencing represents a potential strategy for managing metabolic health and preventing early-onset type 2 diabetes in young women.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10218-10226"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Prevalence of Undiagnosed Dysglycemia Among Reproductive-Age Women in the United States.","authors":"Ahmed Abdelaziz, Noha Hammad, Nuha A ElSayed","doi":"10.1111/dom.71131","DOIUrl":"10.1111/dom.71131","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10846-10848"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline HDL Cholesterol and the Anti-VEGF Injection-Sparing Effect of an SGLT2 Inhibitor in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.","authors":"Ryoichi Ishibashi, Masaya Koshizaka, Kiichi Hirayama, Toshiki Sakai, Tomoaki Tatsumi, Yoko Takatsuna, Takayuki Baba, Yoshiro Maezawa, Koutaro Yokote","doi":"10.1111/dom.71223","DOIUrl":"10.1111/dom.71223","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10891-10894"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Adoption of Generative AI for Carbohydrate Counting in Adults With Type 1 Diabetes.","authors":"Sandra Goncalves, Charline Ponchateau, Céline Coelho, Lysiane Pretre, Marlène Jarlot, Catherine Ducloux, Alfred Penfornis, Coralie Amadou","doi":"10.1111/dom.71309","DOIUrl":"10.1111/dom.71309","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10911-10913"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Assessment of Abdominal Adiposity and Muscle Strength for Atherosclerotic Cardiovascular Disease Risk in UK Biobank: A Comprehensive Analysis From Population Cohort to Multi-Omics Molecular Exploration.","authors":"Jie Luo, Yin Wang, Zhaofu Tan, Genlong Bai, Lifu Sun, Yuting Liu, Ruolin Li, Jiaxing Ke, Jingbo Zhang","doi":"10.1111/dom.71278","DOIUrl":"10.1111/dom.71278","url":null,"abstract":"<p><strong>Background: </strong>Waist circumference (WC) and grip strength (GS) are independently associated with atherosclerotic cardiovascular disease (ASCVD) risk. However, their joint impact remains insufficiently explored. This study aimed to investigate the association between WC, GS and ASCVD risk and to explore the underlying mediating factors.</p><p><strong>Methods: </strong>This prospective cohort study included 271 061 UK Biobank participants. WC was categorised using World Health Organization sex-specific thresholds and GS was categorised into age- and sex-specific tertiles. Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Additive interaction was assessed using the relative excess risk due to interaction (RERI), attributable proportion (AP) and synergy index (SI). Multiple sensitivity and exploratory mediation analyses were performed.</p><p><strong>Results: </strong>During a median follow-up of 14.8 years, 27 189 participants developed ASCVD. High WC and low GS were associated with higher ASCVD risk than their respective reference groups, with HRs of 1.35 (95% CI 1.31-1.39) and 1.14 (95% CI 1.11-1.17), respectively. Participants with both high WC and low GS had the highest risk (HR 1.53, 95% CI 1.46-1.61), with evidence of additive interaction (RERI 0.11, 95% CI 0.03-0.19, AP 7.04%, 95% CI 1.67%-12.41%, SI 1.26, 95% CI 1.01-1.50). Results were consistent across sensitivity analyses. Exploratory mediation analyses identified shared metabolite and protein mediators and implicated inflammatory, immune, metabolic and vascular remodelling pathways.</p><p><strong>Conclusions: </strong>Higher WC and lower GS were independently and jointly associated with incident ASCVD. Their combination identified the highest-risk group and showed modest additive interaction. Exploratory multi-omics analyses identified shared inflammatory and metabolic mediators that may partly underlie these associations, highlighting the value of integrating simple physical measures with molecular signatures for improved ASCVD risk characterisation.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10513-10525"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Observational Study on the Impact of Menstrual Cycle Phases on Carbohydrate Intake, Insulin Delivery and Glycaemia in Women With Type 1 Diabetes Using MiniMed 780G Automated Insulin Delivery System.","authors":"Suresh Rama Chandran, Wei Mian Ang, Gek Hsiang Lim, Gerald Gui Ren Sng, Daphne Gardner","doi":"10.1111/dom.71234","DOIUrl":"10.1111/dom.71234","url":null,"abstract":"<p><strong>Aims: </strong>To quantify changes in carbohydrate intake, insulin delivery and glycaemia across menstrual cycle phases in women with type 1 diabetes using the MiniMed 780G automated insulin delivery system (MM780G).</p><p><strong>Materials and methods: </strong>Women on MM780G provided menstrual cycle data. Continuous glucose monitoring and insulin delivery data were retrieved from the CareLink portal. Daily values for time in range (TIR, 3.9-10 mmol/L), total carbohydrates, total basal, total bolus and total insulin were calculated. Menstrual phases were classified using two methods: Method 1 compared the pre-menses week with the menses week; Method 2 compared five physiological phases with mid-follicular as reference. Linear mixed-effects models with random intercepts for participant and cycle were fitted.</p><p><strong>Results: </strong>Fifteen women (mean age 35.9 years, BMI 23.3 kg/m², HbA1c 50.8 mmol/mol [6.8%]) contributed 118 cycles. In the pre-menses week, carbohydrate intake (β = +0.164 g kg^-1, adjusted p = 0.003), total daily bolus (β = +0.018 U kg^-1, adjusted p = 0.001), total daily basal (β = +0.011 U kg^-1, adjusted p = 0.003) and total daily dose (β = +0.029 U kg^-1, adjusted p < 0.001) were significantly higher than the menses week, yet TIR was lower (β = -3.487 percentage points, adjusted p < 0.001). In Method 2, total daily basal and total daily dose were significantly higher in the late luteal phase, and TIR was lower in the mid luteal phase (β = -3.34 percentage points, adjusted p = 0.007).</p><p><strong>Conclusions: </strong>Menstrual cycle phase is associated with significant changes in carbohydrate intake, insulin delivery and TIR in women using MiniMed 780G. Despite increased insulin delivery, TIR was lower in the luteal phase, suggesting partial adaptation to menstrual cycle-related physiological changes.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10173-10182"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD: A 16-Week, Double-Masked, Randomized Controlled Trial.","authors":"Martha A Belury, Rachel M Cole, Ai Ni, Arunark Kolipaka, Manjunathan Nanjappa, Kristin Thompson, Ali Kalhori, Stephan Zarich, Rolando E Choriego, Rafael Jimenez-Flores, Na Li","doi":"10.1111/dom.71237","DOIUrl":"10.1111/dom.71237","url":null,"abstract":"<p><strong>Background: </strong>Dietary linoleic acid (LA)-rich oils reduce liver fat in healthy adults who are not otherwise undergoing weight loss strategies. Effects on the liver fat in adults with fatty liver disease are unknown.</p><p><strong>Objective: </strong>The objective of this randomized double-masked controlled trial was to compare the effects of a dietary soybean oil (SO) which is high in LA vs. palm oil (PO) which is composed of a mixture of saturated, mono- and polyunsaturated fats, on changes of liver fat level in adults with MAFLD.</p><p><strong>Methods: </strong>Adults with MAFLD were recruited to complete a double-masked, randomized controlled trial consisting of a 2-week run-in period followed by a 16-week dietary intervention. Study foods contained either SO or PO to deliver 30 g oils per day. At week 0 and week 16, liver fat and visceral adipose tissue were measured by ¹H-magnetic resonance spectroscopy imaging and fasting blood was collected for secondary biochemical markers of cardiometabolic disease risk.</p><p><strong>Results: </strong>Sixty-five adults with MAFLD (mean age ~53 y, BMI 36 kg/m²) completed the study. Overall, there was a significant difference in the change of liver fat between SO and PO groups; however, after adjusting for baseline liver fat the diet group differences were no longer significant (p = 0.14). The direct effect of diet group on the change of liver fat was not mediated by weight change (p = 0.11). For within group change, liver fat tended to decrease in SO group (p = 0.11) and tended to increase in PO group (p = 0.11).</p><p><strong>Conclusions: </strong>There was no significant difference for the effect of PO over SO on liver fat change when controlling for baseline liver fat or weight change. Larger trials testing dietary strategies that reduce liver fat in adults with MAFLD in the context of weight change are needed.</p><p><strong>Trail registration: </strong>The WELL study is registered on ClinicalTrials.gov (NCT05199948).</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10648-10663"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database Study.","authors":"Masaya Koshizaka, Ryoichi Ishibashi, Tomoki Ishikawa, Kazuo Goda, Jumpei Sato, Masaru Kitsuregawa, Koutaro Yokote, Naohiro Mitsutake","doi":"10.1111/dom.71209","DOIUrl":"10.1111/dom.71209","url":null,"abstract":"<p><strong>Aims: </strong>Large-scale clinical trials have shown multiple effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs); however, similar evidence for Asian patients is limited. Therefore, using a Japanese large-scale claims-based database, the effects of GLP-1RAs on cardiovascular and cerebrovascular events including mortality were compared with those of other glucose-lowering agents.</p><p><strong>Materials and methods: </strong>Patients with type 2 diabetes (T2D) were identified from a claims database of approximately 1.9 million individuals. Those newly prescribed GLP-1RAs between 2014 and 2021 were assigned to the GLP-1RA group, while those initiating other glucose-lowering agents served as controls. The primary outcome was cardiovascular or cerebrovascular events or all-cause mortality. Logistic regression analysis was performed using explanatory variables, and nearest-neighbour propensity score matching was performed between the groups. The period from the initiation of new medication to event occurrence was calculated and analysed using the Cox proportional hazards model, with a maximum follow-up of 38 months.</p><p><strong>Results: </strong>Among 469 461 eligible patients, 2401 received GLP-1RAs and 53 946 were controls. After propensity matching, 2147 patients remained in each group. The median follow-up was 12 months. No significant difference was observed in 3-point major adverse cardiovascular events (3-point MACE) (GLP-1RA, 7.08% (n = 152) versus control, 8.20% (n = 176); hazard ratio (HR), 0.920; 95% confidence interval (CI) 0.740-1.143, p = 0.450). However, all-cause mortality was lower in the GLP-1RAs group (5.36% (n = 115) versus 7.36% (n = 158), HR 0.776, 95% CI 0.610-0.987, p = 0.039).</p><p><strong>Conclusions: </strong>GLP-1RA showed no association with 3-point MACE difference but showed lower all-cause mortality. These findings possibly reflect residual confounding.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10037-10044"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148710611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oleanolic Acid-Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial.","authors":"Aída García-González, Alejandro Matamoros-Domínguez, Juan Manuel Espinosa-Cabello, Gisela Pérez-Muñoz, Manuel Jesús León Aranda, María Del Carmen Roque-Cuellar, Silvia García-Rey, Andrés Jiménez-Sánchez, Antonio Jesús Martínez-Ortega, Miguel Ángel Mangas-Cruz, Isabel Cerrillo, Javier S Perona, Pedro Pablo García-Luna, Elena María Yubero-Serrano, José María Castellano","doi":"10.1111/dom.71206","DOIUrl":"10.1111/dom.71206","url":null,"abstract":"<p><strong>Aims: </strong>Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive-derived matrices, may modulate AGE metabolism. In this prespecified, exploratory secondary analysis of the OLTRAD trial, we evaluated whether long-term intake of OA-enriched olive oil attenuates kidney function decline in patients with T2DM.</p><p><strong>Methods: </strong>In the OLTRAD randomised controlled trial, 97 patients with T2DM were assigned to consume OA-enriched olive oil (600 mg OA/kg) or control olive oil for 12 months, alongside standard therapy. Kidney outcomes included estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (uACR). Circulating AGEs (methylglyoxal [MG], carboxymethyllysine [CML]), enzymes involved in AGE metabolism (aldose reductase [AR], glyoxalase-I [GloxI]), and oxidative stress markers (ROS and MDA) were assessed.</p><p><strong>Results: </strong>OA-enriched olive oil attenuated eGFR decline relative to control, an effect restricted to participants with mildly impaired eGFR at baseline (60-90 mL/min/1.73 m²; time × group interaction p = 0.010), with no significant interaction among participants with normal baseline eGFR. OA-enriched oil also prevented the rise in uACR observed with control oil. Mechanistically, OA reduced AR concentration and increased GloxI activity, resulting in lower circulating MG, whereas CML remained unchanged. OA-enriched oil further reduced ROS and MDA levels, while MDA increased with control oil.</p><p><strong>Conclusions: </strong>In this exploratory, hypothesis-generating secondary analysis, long-term consumption of OA-enriched olive oil was associated with attenuated kidney function decline in patients with T2DM, an effect limited to those with baseline mildly impaired eGFR. These changes were associated with modulation of AGE-related pathways and reduced oxidative stress. As the trial was powered for glycemic control rather than renal outcomes, larger, adequately powered studies are needed to confirm these findings before their clinical relevance can be established.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov identifier: NCT06030544; https://clinicaltrials.gov/study/NCT06030544.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10195-10209"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Diabetes Risk Models Applied to the Prediction of Incident Dysglycaemia in African and European Populations.","authors":"Melony Fortuin-de Smidt, Patrik Wennberg, Hannah Maike Albers, Charles Agyemang, Felix P Chilunga, Rikard Landberg, Lisa K Micklesfield, Samuel N Darko, Julia Otten, Ellis Owusu-Dabo, Clemens Wittenbecher, Tommy Olsson, Julia H Goedecke, Ina Danquah","doi":"10.1111/dom.71285","DOIUrl":"10.1111/dom.71285","url":null,"abstract":"<p><strong>Aims: </strong>We evaluated overall and sex-specific performance of established diabetes risk models for predicting incident dysglycaemia in African and European populations.</p><p><strong>Materials and methods: </strong>We externally evaluated the African Diabetes Risk model, Finnish Diabetes Risk model, Epidemiological Study on the Insulin Resistance Syndrome model and the personal and clinical Framingham models. Evaluation was performed in three prospective cohorts: the Research on Obesity and Diabetes among African Migrants (RODAM-Pros; migrant and non-migrant Ghanaians; n = 1607), the Middle-aged Soweto cohort (MASC; urban Black South Africans; n = 515) and the Västerbotten Intervention Programme (VIP; Sweden; n = 3044). Dysglycaemia was defined according to American Diabetes Association criteria. Discrimination (c-statistic) and calibration were assessed before and after recalibration.</p><p><strong>Results: </strong>Dysglycaemia developed in 17.7% of RODAM-Pros participants, 35.0% of MASC participants and 27.5% of VIP participants, with median follow-up of 6.7, 6.7 and 9.9 years, respectively. All models demonstrated poor-to-modest discrimination (c-statistic < 0.7). Most models substantially underestimated risk. Recalibration eliminated systematic miscalibration and reduced calibration error to ≤ 2.3% in RODAM-Pros and VIP and ≤ 3.4% in MASC. Performance varied by sex and cohort.</p><p><strong>Conclusions: </strong>Existing diabetes risk prediction models can be applied to predict incident dysglycaemia in both Sub-Saharan African and European populations, but only after recalibration to local risk levels.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"10814-10826"},"PeriodicalIF":6.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13646359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}